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Abstract
Adenoviruses (Ads) have been exploited for use as both vaccine and gene
therapy vectors. All clinical trials to date, using replication defective adenoviruses,
have been conducted with group C members largely because the El deletion can be
complemented by existing cell lines. It has become desirable to establish methods for
propagating non-group C adenoviral serotypes to circumvent pre-existing immunity
as well as to alter and/or improve tropism. Until now, it was thought that only group
eEl-deleted Ads could be propagated on existing cells lines. Thus far, attempts to
propagate non-group C adenoviruses have required alterations to the cell line, which
is suboptimal as a manufacturing platform due to the fact that each cell line would
require extensive safety testing. We have shown that several (and likely all) EI-
deleted group D viruses are able to be complemented by existing cell lines. This is
the first report of a non-group eEl-deleted vector grown in existing cell lines
without modification to either the vector or the cell line. Although these vectors
could be propagated in the existing cell lines, we have found that the addition of
Ad50rf6 within either the EI or E4 region of the Ad24 genome improves both
growth and infectivity of the vectors. Our data indicate that alterations to the E4
region of Ad24 to allow insertion of Ad50rf6 do not appear to have a negative effect
on transgene expression or antibody response to the transgene product. Thus it
appears that E I-deleted altemate serotype viruses can be easily propagated and
'-
should be viable alternatives to the group C adenoviruses as vaccine or gene therapy
vectors. Screening serotypes for low seroprevalence and favorable particle to
infectious particle ratios should allow the development of a panel of vectors that can
be used to administer multiple different vaccines or repeated administration of the
same vaccine or therapy.
Introduction
Vaccine Development
The Institute of Medicine in their publication Vaccines for the 21st Century: A
Tool for Decisionmaking listed over 25 examples of needed vaccines which are
directed against conditions of domestic importance and have the potential to go
through development and licensure within the next 20 years (Stratton 2000). This list
excluded mv as it is already of extremely high priority within the Nlli. The
proposed vaccines included therapeutic as well as sterilizing vaccines and included
diseases such as Hepatitis C Virus, Herpes Simplex Virus, Human Papilloma Virus,
Respiratory Syncytial Virus, Rotavirus, Multiple Sclerosis, Insulin Dependent
Diabetes Mellitus, and Melanoma. This list includes only those diseases which fit
their model for prioritizing vaccine development and did not address emerging
viruses such as Lassa, Hanta, Ebola, and West Nile. Clearly there is great need for
vaccines to prevent present day diseases as well as a need to develop vaccines quickly
as new highly infectious viruses emerge. The SARS outbreak of 2002 was clear
warning that it has become necessary to have a platform in place that could be rapidly
utilized to develop a wide variety of vaccines.
The development and use of vaccines is an extremely cost effective method of
preventing disease in humans. There are many types of vaccines that are being
explored for development such as DNA-. protein-. and peptide-based. as well as both
recombinant bacterial- and recombinant viral-based. Each of these vaccine
approaches has their own advantages and disadvantages in terms of production costs,
safety profile, and immune response elicited. Recombinant viral vectors, such as
adenoviral vectors, may be one of the most promising candidates for development
since the genome has been extensively studied (Horwitz 1990), live adenoviral
vaccines have been proven safe (Ruben 1994), and methods to construct these vectors
are well established (Graham 1991).
Increasingly, understanding the immunobiology of a specific infection will
provide the cues as to how a vaccine capable of generating specific and appropriate
protective immunity can be engineered. For many diseases it is becoming clear that a
comprehensive response rather than one that predominantly activates a single branch
of the immune system may be required for preventing infection. Until the precise type
of immune response required for persistent protection from various pathogens can be
determined, it is reasonable to utilize a system that can elicit responses from more
than one branch of the immune system. Adenoviruses have been shown to generate
humoral, secretory, and cell-mediated immunity (Huge, Richardson et al. 1997).
Adenovirus
Adenoviruses have recently received much attention as expression vectors for
use in gene therapy, but have been considered and evaluated as vaccine vectors for
years (Imler 1995: Russell 2000). There are several advantages to adenoviral based
. ~
vaccines. Ad2 and Ad5. the serotypes on which most vectors are based. can be
grown to high titer in conventional tissue culture systems and are easily purified.
They have a genetically stable DNA genome with known sequence which is less
likely to mutate than an RNA genome. Ad2 and Ad5 are well characterized both
genetically and biochemically. They are non-pathogenic to humans, can be
administered orally, and infect a wide range of cells. Although it is known that
adenoviruses can transform cells and cause tumors in newborn rodents (Nevins 1996),
no evidence of adenoviral DNA in human tumors has been reported (Green, Wold et
a1. 1979; Wold, Mackey et a1. 1979).
Adenovirus structure
Adenoviruses have linear double stranded DNA genomes encapsulated in an
icosahedral protein shell measuring 70-100 nm in diameter. There are over 50 human
adenovirus serotypes of variable prevalence and disease association whose genomes
range from 30 to 38 Kb. These serotypes have been categorized into 'six subgroups,
A-F, based on their ability to agglutinate red blood cells (Hierholzer 1973). Sub-
groupings based upon base composition, restriction digest pattern, oncogenicity in
rodents, or relatedness of tumor antigens fall largely in agreement with the
hemagglutination standard. A sub-group may contain as many as thirty members as
found in group D or may contain a lone member as is Ad4 in group E. Although
homology can be high within a sub-group (99-100% in group C); it is relatively low
between subgroups (only 10-15 %). Most of the structural studies have centered on
Ad2 and AdS. These group-C members have been sequenced in their entirety and
were found to be 9SC;C identical. The majority of the differences are found in the fiber
and hexon coding regions. hence their different type specificity. All adenoviral
genomes examined to date show the same organizational pattern, that is; genes
encoding specific functions are localized in the same position on the viral
chromosome.
Adenoviral Organization
The viral chromosome carries five early transcription units (EIA, EIB, E2,
-
E3, and E4), two delayed early units (IX and IVa2) and one late unit. The late unit
(major late) is subsequently processed to form five families of late rllRNA's (LI to
L5). Conventionally, the adenoviral genome is drawn with the EIA gene at the left
end (Figure 1). In general, the-individual transcription units encode a series of
polypeptides with related functions. The EIA unit encodes two proteins that activate
transcription and induce the host to enter S-phase of the cell cycle. The two EIB
proteins induce cell growth in conjunction with EIA products. The three E2 proteins
all serve direct roles in DNA replication, while the E3 proteins modulate the response
of the host to the adenovirus infection. It is the role of the late family of mRNA's to
produce and assemble capsid components. Only the E4 unit seems to encode a more
diverse set of functions; mediating transcriptional regulation and mRNA transport as
well as DNA replication (Russell 2000).
Regions for Transgene Insertion
Commonly. the El and E3 regions of Ad5 are removed from the adenoviral
\'ector rendering it replication defective and allowing for the insertion of the desired
therapeutic gene or antigen of interest.
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Figure 1. The genome organization of human Ad5. At the top of the figure, the
genome is represented as a line with lengths marked in kbp from the conventional left
end. Thick arrows represent early and late transcription units (black and grey,
respectively). Open boxes represent the major introns. The E4 gene is enlarged as a
line scale with lengths in bp. The primary transcript is shown as a black arrow in a 5'
to 3' direction and each of the potential encoded proteins is shown as an open box;
proteins whose coding regions are split by intron sequences are shown as boxes
linked by a line. Overlapping proteins have different polypeptide sequences unless
they share the same number (Leppard 1997).
s
These deletions, as well as the ability of the Ad5 capsid to package approximately
105% of the wild-type genome length, allow vectors to accommodate up to 8Kb of
foreign sequence (Bett, Prevec et a1. 1993; Bett, Haddara et a1. 1994). As mentioned
above, the products of the E3 region are involved in evasion of the host immune
response and therefore may be important in a natural infection, but are not essential
for growth ill vitro. E1, however, is required for growth and E1-deleted viruses must
be propagated in E1 complementing cell lines such as 293 or PER.C6™ (Graham,
Smiley et a1. 1977; Fallaux, Bout et a1. 1998). These cell lines have been stably
transfected with the E1A and E1B regions of the Ad5 genome which are able to
provide, in trans, all the required functions for adenoviral propagation. Deletion of
E1 prevents replication ill vivo once the virus has been delivered to the patient. The
limitation to developing all adenoviral serotypes as potential vaccine candidates is
that the currently available cell lines are only capable of complementing group-C
adenoviruses.
Pre-existing immunity
A concern for the development of gene therapy or vaccine vectors based on
the AdS serotype is pre-existing immunity. The humoral immune response to a
natural AdS infection can result in the production of anti-Ad5 neutralizing antibodies
which would reduce the effectiveness of an AdS based vaccine. The group C
serotypes (Ads 1.2. and 6) along with AdS shO\\' high seroprevalence in the
9
population. Almost 30% of 3-6 years olds in Rome have antibodies to adenoviruses
1, 2, and 5 and between 60-80% of adults tested in the Belgium population had
neutralizing antibodies to Ads 1,2,and 5 (Figure 2)(Vogels, Zuijdgeest et al. 2003).
All clinical trials underway thus far utilize either the Ad2 or Ad5 serotypes. Pre-
existing immunity not only poses a problem to primary immunizations, but also to re-
administration of the same vector or different vaccines based on the same serotype.
Generating a panel of distinct vectors based on different serotypes would allow the
development of multiple vaccines and the re-administration of the same vaccine.
Additional advantages in developing alternate serotypes include altered tissue tropism
and/or increased transduction efficiency that may benefit both vaccine and gene
therapy applications (Gall, Kass-Eisler et al. 1996; Chillon, Bosch et al. 1999).
Alternate Serotypes
Because of the seroprevalence of the group C members, non-group C
serotypes may be the most attractive for vector development. There are over 50
human serotypes each of which could serve as a vaccine delivery vehicle. It is known
that only group C serotypes can be complemented by the Ad5El region in the 293 or
PER.C6™ cell lines. This means that less than 10% of the known serotypes are able
to grow as defective vectors in the currently available Ad5 El-containing cell lines.
Straightforward methods exist for developing and propagating group C adenoviral
vectors. If these methods could be extended to include the many other adenoviral
serotypes. a true panel of vehicles would be available for insertion of target antigens
or transgenes and could be rapidly tested for efficacy.
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FIG 2. Low seroprevalance of Ad24 (Group D) in healthy individuals relative to
other serotypes especially Ads 2 and 5 (Group C). One hundred serum samples from
the Belgium population (average 30.8 years; range, 18-62 years; 50% female) were
tested for neutralizing antibody against human adenovirus types. Shown on the y axis
is the percentage of sera that inhibited virus replication> 90% at the lowest dilution.
Types are ranked according to their classification in subgroups. Asterixes indicate
serotypes of particular relevance to this study.
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The first report of an EIA deleted non-subgroup C vector that could
propagate in existing cell lines was published by Abrahamsen et a1. in 1997
(Abrahamsen, Kong et a1. 1997). The authors set out to create an Ad7 EIA-EIB-
vector expressing the chloramphenicol acetyltransferase (CAT) gene and attempted to
grow it on the 293 cell line. After repeated attempts to plaque purify this virus were
unsuccessful the authors concluded the 293 cell line was not able to fully complement
the Ad7a-CAT virus. Since all of the known EIA interactions are protein-protein
interactions involving host cell factors, the EIA gene products were eliminated as
possible candidates for the limit to complementation. The EIB gene products, on the
other hand, interact with both host and viral proteins. Interactions between EIB and
E4 proteins, specifically EIB-55kDa and E40rf6, were thought to be responsible for
the failure of complementation of Ad7a-CAT on 293 cells. An Ad50rf6 containing
cell line was in existence (Brough, Lizonova et a1. 1996) and attempts to plaque
purify the virus on the 293-0rf6 cell line proved successful and provided stocks
comparable to the yields of an Ad5-based vector. The virus appears to be able to
transduce A549 cells as efficiently as Ad5-based vectors and can infect a variety of
tissues when injected into mice. The usc of cell lines expressing both adenovirus El
and E4 gene products proved to be a critical clement that the authors had not
anticipated.
E1-55kDa-E40rf6 functional interactions
The late phase of an adenoviral infection is characterized by the transport of
viralmRNA out of the nucleus and into the cytoplasm while most cellular mRNA
remains sequestered in the nucleus. A complex of two adenoviral proteins, E1B-55
kDa and E40rf6 of the human subgroup C adenoviruses has been implicated in this
selective transport of late mRNAs. These proteins have also been shown to regulate
late viral gene expression. Although the molecular mechanisms by which these viral
proteins subvert cellular pathways of nuclear export have not yet been fully
elucidated, much has been learned about the requirements for these proteins.
The absence of functional E1B-55 kPa protein from infected HeLa cells leads
to reduced cytoplasmic concentrations of viral late mRNA's (Babiss, Ginsberg et al.
1985). Leppard and Shenk, analyzing the flow of newly synthesized RNA through a
series of biochemically defined nuclear fractions, showed that major late (ML) RNA
is made in a nuclear matrix fraction of infected cells and subsequently accumulates in
a nuclear soluble fraction, transits through a nuclear membrane fraction, and enters
into the cytoplasm (Leppard and Shenk 1989). Absence of E1B-55 kDa protein
resulted in a significant reduction of ML RNA in the nuclear soluble fraction with
degradation of the RNA within the nucleus. Since the majority of the ML RNAs
reaching the fraction were correctly processed, it was concluded that the E1B-55 kDa
protein mediates an intranuclear reaction necessary for efficient export of late
mRNAs to the cytoplasm.
Similar to EIB-55 kDa, E40rf6 protein encodes functions which are required
for viral DNA synthesis. late viral gene expression and host cell shut off. In addition.
the absence of E40rf6 results in decreased intranuclear concentrations of viral i\tL
mRNA precursors greater than can be accounted for by reduced rates of ML
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transcription and which are therefore attributed to decreased stability of these RNA
molecules (Bridge and Ketner 1990). E4 deletion mutants that express the E40rf6
protein in the absence of all other E4 encoded proteins replicate to near WT levels
(Halbert, Cutt et al. 1985). In addition, replication of a completely E4 deleted virus
could be restored by transfecting the cells infected by the mutant virus with a cDNA
expressing the E40rf6 protein. Since E1B-55kDa and E40rf6 were found to
associate in infected cells (Sarnow, Hearing et al. 1984) and can be recovered as a
complex (Cutt, Shenk et al. 1987 Sarnow, Ho et al. 1982), it has been accepted for
sometime that the regulation of mRNA export in adenovirus infected cells is mediated
by the E1B-55 kDa protein in association with the E40rf6 protein (Dobner and
Kzhyshkowska 2001). This concept is further supported by the fact that double
mutants show a reduction in late protein synthesis that is virtually identical to the
reduction observed for viruses that bear either of the single mutations (Cutt, Shenk et
al. 1987).
A characteristic feature of eukaryotic proteins that convey macromolecules
from the nucleus to the cytoplasm or vice versa is the ability to shuttle between these
compartments. The human immunodeficiency virus type 1 (HIV-I) encodes an
mRNA export regulator, the Rev protein, which also exhibits this shuttling ability.
Rev protein promotes export of viral mRNAs that retain introns and splice sites by
binding to an intronic sequence within the mRNAs. the Rev-response clement. This
was the first export receptor for RNA to be identified unambiguously and has guided
inycstigations into the shuttling of the adcnoyiral proteins E1B-55 kDa and E40rf6.
15
Goodrum et al. detennined the localization of the two proteins in the absence of other
adenoviral proteins (Goodrum, Shenk et al. 1996). When expressed by transfection in
human cells, the EIB protein was predominantly cytoplasmic and typically excluded
from the nucleus. The E40rf6 protein, on the other hand, accumulated in the nucleus
upon transfection. Interestingly, when the proteins were co-expressed by transfection
in human cells, the EIB protein co-localized with the E4 protein in the nucleus
(Goodrum and Ornelles 1999). The authors also identified the EIB-55 kDa -E40rf6
complex in transfected HeLa cells by immunoprecipitation. Physical evidence for
complex formation has also been demonstrated by the ability of EIB-55 kDa specific
antibodies to indirectly immunoprecipitate the E40rf6 protein from Ad infected cells
(Rubenwolf, Schutt et al. 1997 Samow, Hearing et al. 1984) and from cellular lysates
reconstituted ill vitro (Sarnow, Hearing et al. 1984). Immunofluorescence and
electron microscopy have demonstrated that the E40rf6- EIB-55 kDa protein
complex localizes to the peripheries of the sites of viral transcription and RNA
processing within the nucleus of Ad5 infected cells (Ornelles and Shenk 1991). In
the ~~sence of a functional E40rf6 protein, the EIB-55 kDa polypeptide fails to
associate with the viral inclusion bodies suggesting that the E40rf6 protein targets the
El B-55 kDa polypeptides to these centers.
There have been several structural clements identified within Ad50rf6 that are
required for proper EIB-55 kDa -E40rf6 function (Figure 3).
16
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Figure 3. Functional features of the Ad5 E40rf6 protein. The E40rf6 protein is
represented by the large box within which are shown the locations of possible nuclear
localization signals (NLS patterned areas), a nuclear export signal (NES blue box), a
potential zinc binding domain (green box), and an amphipathic alpha helix (fuchsia
box). The three regions reported to bind the EIB 55-kDa protein are indicated by
double arrows.
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A short leucine rich sequence located between positions 83-93 of the 294 aa
Ad5E40rf6 protein, which resembles the nuclear export signal (NES) of the HIV-l
Rev protein, was shown to be necessary for shuttling of the EIB-55 kDa-E40rf6
complex and sufficient to mediate export when fused to a heterologous GST protein
(Dobbelstein, Roth et al. 1997). Mutations within the NES considerably reduce virus
yields, viral DNA synthesis, late hexon protein production, and cytoplasmic
accumulation of L5 mRNA in transfectionJinfection experiments in BeLa cells. The
central region of Ad50rf6 consisting of several conserved cysteines and histidines
(HCHC) suggested there may be a zinc binding domain (Boyer and Ketner 2000).
The E40rf6 protein, solubilized from insect cells infected with a baculovirus vector,
was shown to bind Zinc in a blotting assay. Substitution of any of seven histidine and
cysteine residues, conserved among most adenoviral serotypes, impaired several
activities including complementation of an E4 mutant virus by transiently synthesized
Orf6 protein, as well as binding to and re-localization of the E1B-55 kDa protein.
A structural model derived by application of fold-recognition and comparative
protein modeling methods is consistent with this hypothesis (Brown, Gonzalez et al.
2001). This model also accounts for the only structural feature of the E40rf6 protein
for which there is experimental evidence - a C-terminal amphipathic alpha helix
fonned by residues 239-255. A peptide analogue of this arginine rich sequence was
shown to adopt a helical confomlation in solution (Orlando and Ornelles 1999).
Deletion of residues 241-250 or proline substitution of Arg239. Arg241. or Lcu245
abolished the ability of the E4 protein to direct nuclear localization of the E1B-55
19
kDa protein when the two were synthesized in HeLa cells. The latter two
substitutions also impaired complementation of a mutant virus deleted in E4 Orfl, 2,
3, and 6 (Bridge and Ketner 1989), by transiently synthesized E40rf6 protein. The
authors concluded that the alpha helix is important to E4 function because it was
required to direct nuclear localization of the E1B-55 kDa protein. When expressed
alone, E40rf6 does not move from human to murine nuclei in heterokaryons formed
between co-transfected HeLa and non-transfected mouse Balb-c 3T3 cells. This
nuclear retention can be reversed by co-transfection of E1B-55 kDa or by mutations
within the arginine rich region that overlap one of the putative E40rf6 NLS's. Based
on these observations, it was proposed that E40rf6 contains a nuclear retention like
sequence (NRS) in the carboxy-terminal region that is dominant over the NLSs
located at either termini of the E40rf6 protein.
E40rf6-E1B-55 kDa physical interactions
Currently, there are three reports defining regions within E4 Orf6 that are
critical for binding to EIB-55 kDa (Figure 3). Rubenwolf et aI., using both protein
blot and coimmunoprecipitation assays, showed that the amino terminal end of the
E40rf6 protein is required for binding to EIB-55 kDa ill vivo and;'l vitro
(Rubenwolf, Schutt et al. 1997). A series of deletion mutants were made and tested
for the ability to bind El B-55 kDa (Querido, Morrison et al. 200 1). Of the 23
different deletion mutants and seyeral point mutants tested. only two. namely dll-55
and dll-lOS failed to interact with EIB-55 kDa. This would appear to support
Rubenwolf's findings (Rubenwolf. Schutt et al. 1997) that the amino tem1inal 55 aa
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are necessary for binding, but the deletion mutants dll-38 and dll08-294, which were
also tested in Queridos' experiments, showed normal binding to EIB-55 kDa. It was
therefore concluded from these experiments that the binding site for the E40rf6
protein would have to be located between residues 39 and 107. Finally, Weigel and
Dobbelstein demonstrated that a third region could bind EIB-55 kDa (Weigel and
Dobbelstein 2000). In order to map the activities of E40rf6, several E40rf6 mutant
expression plasmids were created. In these mutants, small amino acid deletions were
introduced at residues that were predicted to be exposed to the surface by a computer
based secondary structure calculation (Rost and Sander 1993). After Westerns were
performed to confirm near WT ORF6 expression levels, the mutants were tested for
their ability to relocalize EIB-55 kDa. Transient transfection of HeLa cells with
EIB-55 kDa and E40rf6 expression plasmids followed by simultaneous
immunostaining of the two proteins revealed that only deletion of amino acids 225-
232 abolished the re-Iocalization ability of E40rf6. This deletion removes a putative
amphipathic and arginine rich alpha helix from E40rf6 (Orlando and Omelles 1999).
To further examine this finding, especially in light of the two previously reported
EIB-55 kDa binding regions, both E40rf6 and E40rf6i1225-232 were generated by
transcription and translation in vitro. The proteins were incubated with a lysate from
293 cells that contains E1B-55 kDa. Immunoprecipitation was performed using an
antibody to El B-55 kDa. Considerable amounts of E40rf6 were precipitated in the
presence of El B-55 kDa but not in its absence. E40rf60225-232 largely failed to co-
precipitate with El B-55 kDa indicating that this region. if not necessary. is at \cast
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important for the interaction of the two proteins. Next, virus growth in the context of
this mutant was examined. Expression plasmids for E4orf6 and mutants were
transfected into HeLa cells followed by infection with an E4 deleted virus (Halbert,
Cutt et al. 1985). This virus is unable to replicate at 10w]TIoi (Huang and Hearing
1989). The presence of transiently expressed E40rf6, however, enables the virus to
replicate and leads to the production of new virus particles. Most mutations resulted
in little or no detectable loss in virus production, but the E40rf6.0.225-232 mutant that
was incapable of re-localizing EIB-55 kDa also failed to support virus production.
Given the loss in virus production that is induced by the removal ofresidues 225-232
from E40rf6 the authors attempted to determine which step in virus replication might
be dependent on this domain. To determine if the reduction in virus yield was
accompanied by a loss in late viral protein synthesis when residues 225-232 were
mutated, the amount of hexon protein was measured following transfection and
infection as described above. E40rf6 supported late protein production but no hexon
protein could be detected in the presence of E40rf6.0.225-232. Therefore, not only
had an EIB-55 kDa binding region been defined within E40rf6, the effects of the
absence of this region had been demonstrated on EIB-55 kDa - relocalization as well
as on synthesis of viral DNA, mRNA, and proteins. Of the three domains reported to
bind EIB-55 kDa, only 225-232 was shown to have effects on relocalization and
several other phenotypes long associated with proper functioning of the two proteins.
Strategies for enabling complementation
One possible explanation for the lack of cross complementation of a non-
group C adenovirus on an Ad5 El-containing cell line is that a direct interaction
between the EIB-55 kDa protein and the E40rf6 protein is unable to occur properly
when the proteins do not originate from the same subgroup. Because the proper EIB-
55 kDa-E40rf6 interaction has been shown to be involved in many processes required
for maximal virus production, including viral DNA synthesis, host cell shut-off, as
well as late viral mRNA splicing and transport, and the addition of a sero-matched
Ad50rf6 to a cell line containing Ad5EIB-55 kDa resulted in complementation of an
Ad? El-deleted vector, it may be that there is a requirement for sero-matched El and
E4 regions. There are several approaches for developing systems which would
provide sero-matched proteins to allow propagation of other Ad serotypes. The
creation of new complementing cell lines (eCLs) for each subgroup is a possibility,
but the task has thus far proven difficult due to the surprising resistance of human
cells to transformation by El. Despite attempts to transfect primary human
keratinocytes, fibroblasts, hepatocytes, and urothelial cells, the 293 cell line was the
only available cell line for production of replication defective adenovirus for nearly
two decades (Gallimore, Grand et al: 1986). Recently, the human embryonal
retinoblast cell line (PER.C6™) has been used to propagate Ad5 EI-deleted vectors
(Fall am, Bout et al. 1998) and fetal porcine retinal cells containing Ad5E 1 have been
used to complement the E1A and/or E1B~mJI1 (l9kDa) defect of porcine adenovirus 3
(PAV-3) (Zhou and Tikoo 2001). A recent paper suggests that Ad5EI can be
efficiently transformed into primary human amniocytes (Schiedner, Hertel et al.
2000). Although a possibility, the generation of multiple cell lines expressing El
genes for each subgroup would be undesirable from a manufacturing platform
standpoint due to the extensive testing that is required to demonstrate that a cell line
is safe for producing vaccines for human use.
Addition of Ad5 E40rf6 to the PERC6™ cell line is another viable strategy
based on the ability of Ad7 to grow in the 293-0rf6 cell line. These cell lines were
developed for complementation of E4-deleted group C viruses but it appears that they
could be used to propagate alternate serotypes as well. Orf6 expression from the cell
line would require a regulable promoter as it is known that E4 gene products can be
toxic to cells (Chirmule, Hughes et al. 1998). There are intellectual property issues
that would complicate the use of this method. More importantly, however, is the
purification process which would be required to remove the compound, used to
induce E40rf6 gene expression, from the final vaccine product.
Modification of existing cell lines is yet another option. Addition of an
alternate serotypes' EIB-55 kDa to an existing cell line has proven effective in two
models. Vogels has created an Ad35 El-deleted vector that can grow in PER.C6™.
This group confirmed that the Ad5 based complementing cell line, PER.C6™, was
unable to fully complement El-deleted Ad35 vectors (Vogels, Zuijdgeest et al. 2003).
In an effort to determine which proteins are essential for an Ad35 vector to replicate
in PER.C6™ . a series of vectors were constructed that carry different parts of the
Ad35 EI region. Subscquent transfections into PER.C6™ dcmonstrated that the gene
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encoding the EIB-55 kDa protein is minimally required to obtain a stable Ad35 El-
deleted virus. After stable transfection of PER.C6™ cells with the Ad35 EIB-55
kDa gene was established, the Ad35El-deleted virus was able to be propagated. An
El-deleted porcine adenovirus has also been propagated for use as a potential vaccine
delivery system (Zakhartchouk, Zhou et al. 2003). Initial efforts produced a porcine
adenovirus 3 (PAV-3) deleted in EIA and EIBsmall (l9kDa) which was able to grow
on fetal porcine retinal cells that had been transformed with the El region of human
Ad5 (Zhou and Tikoo 2001). Attempts made to rescue a recombinant vector
containing an insertional inactivation/deletion of EIBlarge (55kDa) on this same cell
line were unsuccessful. It seemed as though EIBlarge protein from PAV-3 was
required for rescuing the EIBlarge-deleted PAV-3. Construction of a new cell line
VRIBL, w~ich expresses EIBlarge protein could support the replication of the
EIBlarge inactivated mutant, PAV-3, alone and with a transgene in El. Generation
of individual cell lines for each serotype is not an efficient method for propagation of
alternate serotypes.
A more practical approach would be to devise a system to easily alter the
adenoviral vector itself, as opposed to the cell line, to include the entire E4 or E40rf6
region of Ad5 in the viral genome of the alternate serotype. There are straightforward
methods available to circularize adenoviral genomes of virtually any serotype via
bacterial recombination between ITR (Inverted Ternlinal Repeat) cassettes and wild-
type viral DNA for utilization as a plasmid-based vector which can be rescued into
virus (Chartier. Degryse et al. 1996). Addition of Ad5E40rf6 into the EI. EJ or E4
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region of the alternate serotype might allow growth in existing cell lines. Once
validated, the PER.C6™ cell line would be ideal in that it could support the growth of
all serotypes. Safety testing would remain exclusively related to the vector, which
would be the requirement for any novel vaccine candidate.
In order to test whether a sero-matched EIB-55 kDa -E40rf6 interaction is
sufficient for propagation of an alternate serotype, several vectors were constructed
which contained Ad50rf6 within the genome of Adenovirus 24. Vectors in which
Ad50rf6 was placed in either the Ad24 El region or the Ad24 E4 region were
generated. Given the data which demonstrates the importance of amino acids 225-232
within Ad50rf6 for its interaction with Ad5EIB-55kDa, it was decided to also design
a vector in which the Ad24 amino acid sequence within this region was changed to
the Ad5 sequence. This strategy minimized disruption to the native E4 region by
only altering specific amino acids within E4orf6 known to be involved in EIB-55
kDa complex formation. Upon completion of vector construction, each vector was
tested for growth, infectivity, transgene expression levels, and ability to elicit an
antibody response. The extent to which these viruses were able to perform, especially
when compared to an Ad5 vector, was determined.
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Materials and Methods
A. BACTERIAL CULTURES
XLI-Blue cells (Stratagene #200249) were grown in IX LBroth
(lOgIL NaCI, lOgIL Bacto Tryptone, 5gIL Yeast extract) or on solid LB agar
(TEKNOVA Cat # L5104 1% tryptone, 0.5% yeast extract, 1.0% sodium
chloride, 1.5% agar) at 37°. Bacteria containing plasmids with ampicillin
resistance were grown in media supplemented with 100 Jlg/ml ampicillin.
BJ5183 (recBC sbcBC) cells (Hanahan 1983) were used to allow
recombination of homologous sequences in order to circularize wild type
genomes as well as introduce modifications into the El and E4 regions of the
viral genome.
B. MAMMALIAN CELLS AND IN VITRO ANALYSIS
Two mammalian cell lines were used in the course of this study; 293
cells (human embryonic kidney cells that constitutively express the left 12%
of the Ad5 genome; (Graham, Smiley et al. 1977), and PER.C6™ cells
(human embryonic retinoblasts containing Ad5 nt 459-3510: (Fall aux. Bout et
al. 1998).
293 cells were maintained in alpha MEM (Gibco 12561-049)
containing 10% FBS (Hyclone #SH30070.03) and penicillin streptomycin
glutamine (Gibco # 10378-016).
PER.C6™ cells were maintained in Williams E media (Hyclone #
SH3A992.0l) containing 10% FBS (Hyclone #SH30070.03) and penicillin
streptomycin glutamine (Gibco # 10378-016).
C. IN VITRO ANALYSIS
1. Replication Kinetics
To determine if the growth kinetics of the Ad24 constructs had been
affected by the alterations to the genome, growth curves were performed.
6-well plates were seeded with PER.C6™ cells on day 1. On day 3 viruses
were infected at moi 3000 onto all 6 wells of the plate in 500 ~l growth media
for 30 minutes. An additional 4.5 ml of media was added to the cells and they
were placed at 37°, 5% C02. Cells and media were harvested at the
designated time-points by scraping the wells and pipetting off the cells and
media. Samples were frozen at -70° until all time-points had been collected.
Genome Quantitation Assays (GQAs) were performed at a 1-1000 dilution on
samples in triplicate against a standard curve (l06-1O~ genomes). Because this
quantitation is done on crude cell extracts and not banded virus. both
packaged and un-packaged DNA is reflected in the genome number. If
serotypes naturally differ in their packaging efficiency or if alteration of the
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E4 region would somehow affect this parameter, we may have an
overestimate of the actual number of particles that could even be capable of
infecting a cell. Therefore, GQA's were run on the samples both before and
after treatment with DNase. The untreated sample genome number was
divided by the Dnase-treated sample genome number to obtain a total genome
to packaged genome ratio for each construct. All constructs are well within
the 2-3 fold range of variability of the GQA assay. There does not appear to
be any naturally occurring difference in packaging efficiency between Ad5
and Ad24 viruses nor any artificial difference created by the modifications in
the E4-region of the group D viruses. Samples from each time-point
underwent 3 cycles of freezing and thawing. The cell debris was pelleted and
1O1l1 of the supernatant was diluted 1000 fold in A105. Next, 190111 of this
dilution was treated with 1O1l1 Dnase (Amersham 27-0514-02) for 1hour at
37°. The Dnase was inactivated by the addition of 5111 of 0.5M EDTA and
incubation at 80° for 10 minutes. An equal volume of treated or untreated
sample was incubated with SOIlI of 0.2 % SDS for 10 minutes at 56°. The
samples were allowed to cool for 10 minutes at room temperature and then
were diluted 100 fold in H20. Finally,lOllI of each sample was loaded in
triplicate onto an optical PCR plate along with 40pl reaction mixture.
Conditions remain the same for all QPCR based applications. (See Viral
Vector Quantitation for sequences). Data is graphed in genomes/ml oyer
time.
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2. Productivity Assays
In order to determine the number of viral particles on a per cell basis,
productivity assays were performed. PER.C6™ cells were seeded at Day 1 in
T25 flasks. On day three the cells were counted and virus was infected in
triplicate onto the cells at moi 200 in Iml growth media. After 1 hour, 4 ml
media was added to the flasks. The cells were incubated at 5% C02, 37°C for
72 hours. Cells and media were collected and frozen at -70°C until assayed.
The samples underwent three cycles of freezing in a dry ice ethanol bath
followed by thawing in a 37°C water bath. The samples were then spun at
3,000 rpm to pellet cell debris. A lOJll aliquot of the samples was removed
into 190Jll A105/AI95. Then, 190Jll of this dilution was placed into a fresh
tube and lOJll of Dnase was added. The samples were incubated at 37°C for 1
hour. To inactivate the Dnase, 5Jll 0.5M EDTA was added to the tubes and
they were then placed at 80°C for 10 minutes. Samples were then lysed by
incubating 50Jll with an equal volume of 0.2% SDS at 56°C for 10 minutes.
The samples were allowed to coolon the bench top for 10 minutes. A lO~tl
aliquot of the cooled sample was placed into a fresh tube containing 990pl
H:;O. Then. 1O1l1 of the final dilution was assayed in triplicate along with
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standard curve at 106_103. (See Viral Vector Quantitation for sequences) and
run on ABI 7700 (See Viral Vector Quantitation for conditions). Genomes/
ml X 5ml harvest volume / number of cells per plate yields viral particles/
cell.
3. Infectious Titer
The infectivity of the adenoviral stocks was measured using a TCID50
end-point dilution method in a 96 well format. The human embryonic
retinoblast cell line (PER.C6™) was used to allow efficient replication of the
El-deleted recombinant adenoviral constructs. Wells of the 96 well plate
infected with adenovirus are revealed by amplification of target viral DNA
using quantitative PCR. PER.C6™ cells were seeded at 5 X 104 cells/well
in 150JlI growth media in columns 1-12 of 96-well plates. Column 6 is a cell
alone control. The cells were infected 48 hours after seeding. Virus was
diluted to 104_107 in Iml media. The viral dilution was placed into a reagent
reservoir, and using a multichannel pipet, 75JlI was dispensed into column 1
with 8 replicates (Rows A-H). The virus was dispersed thoroughly but gently
by mixing three times with the pipet. Again, using a multi-channel pipet, 75~t1
was transferred to column 2 and mixed in the same manner. This procedure is
continued across the plate. with the exception of the column 6 control. through
column 12. Finally.75~t1 was remoycd from column 12 and discarded. The
cclls wcre incubatcd at 3T'C. SS-C0 2 for 12 days. Cclls wcre harycstcd by
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adding 50111 of 1.44% Triton X-lOO (Roche 1-332-481) to all wells of the 96-
well plate and mixing 5X. The plates were then sealed with foil covers and
frozen at -70°. For QPCR, the plates were thawed and samples diluted
1-1000 in H20. A 10111 aliquot of the diluted material was placed into a 96
well optical plate along with 40111 of reaction mix and run according to
parameters in Viral Vector Genome Quantitation. Data was exported into an
Excel spreadsheet and infection positive wells were scored by a CT value of
39 or below. The Spearman-Karber method was used to calculate the tissue
culture infectious dose 50%.
D. ENZYMES
Restriction enzymes were purchased from Roche Molecular Biochemicals
or from New England Biolabs (NEB) Ltd. Enzymes were used according to
manufacturers recommendations with the reaction buffers provided.
E. RECOMBINANT DNA TECHNIQUES
1. DNA Restriction Digests
DNA restriction digests were used for both cloning and screening
'-' .... '-'
purposes. Reactions were carried out for a minimum of 1 hour at thc
appropriatcd tc.mperature in the rccommended buffer.
2. Small and large scale plasmid preparations
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(Plasmid DNA was prepared to the desired scale through the use of
Qiagen Qiaprep 96 turbo core kit on a Bio robot 9600 for mini prep DNA
(Qiagen # 27173), or with midi ( Qiagen # 12243) or maxi ( Qiagen # 12263 )
kits. Protocols supplied by the manufacturer were followed and DNA was
eluted and stored in H20.
3. Viral DNA purification
To obtain purified viral DNA for labeling and sequencing, equal
volumes of IX pronase digestion buffer (0.05% (w/v) pronase in 10 mM Tris,
pH 7.5,10 mM EDTA and 0.5% (w/v) SDS) and CsCI purified virus were
mixed and incubated at 37° for 2 hours. The digested virus was then phenol
extracted once and viral DNA precipitated with two volumes of 96% ethanol.
The DNA pellet was then dried, resuspended in H20 and quantified by OD26o•
4. Agarose Gel Electrophoresis
Horizontal 1% agarose (Gibco # 15510-027) gels were run in TAE
(Gibco # 24710-030) +EtBr.
Labeled gels were run to confirm the identity and structure of virus
constructs. Digests containing 100ng of purified viral DNA were set up with
HindlI! in a total volume of 20~.tl. HindlI! is used because it yields a
distinctive digestion pattern and provides the 5' overhang necessary for end
labeling with Klenow. For comparison the pre-Adeno plasmid DNA used to
generate the virus was also digested and labeled. The pre-Ad plasmid is
digested with HindlI! and PlIlC[ which releases the ITR's from plasmid
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sequences making the comparison to the viral DNA pattern more
straightforward. After digestion at 37°C for several hours, 5JlI reaction mix
(25Jl12mM dNTP minus dATP, 5JlllOX Buffer B, 5JlIIJlCi [a33P]dATP, 5JlI
Klenow enzyme, and lOJlI dH20) was added to each digest. Marker DNA
(lKb DNA ladder) was also labeled (0.5JlI lKb DNA ladder, 2.0JlII0X
Buffer Band 17.5JlI H20). The tubes were incubated at 37°C for 15 minutes
and then 5JlI gel loading dye was added to each tube. Samples were loaded
onto a 0.7% agarose gel and run in TAB buffer ON at - 50V. The gel was
fixed in 10% acetic acid for 30 minutes and rinsed in H20. The gel was dried
on a gel dryer and exposed to film.
5. Isolation of DNA fragments from agarose gels
DNA fragments were isolated on 1% agarose gels. The desired bands
were excised, weighed, and treated according to the protocol supplied in the
QIAquick gel extraction kit (Qiagen # 28704). DNA was eluted in 30-50JlI
H20 depending on original band size and desired final concentration.
6. Bacterial Transfonnation
For transfonnation of XLI-Blue cells, 100JlI of gently thawed bacteria
were placed into a round bottom test tube along with O.I-IJlg of DNA and
incubated on ice for 30 minutes. The cells were then heat shocked at 42° for
45 seconds and returned to icc for one minutc. SOC (Gibco # 15544-034) was
added to 1ml final yolumc and the bacteria werc allowed to recoycr at 37°.
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with shaking, for one hour. Transfonnations were plated on LB agar using
appropriate dilutions and antibiotic selection.
For recombination in BJ5183 cells, approximately 200ng of each DNA
fragment was mixed with 100~1 cells in a round bottom tube. Transfonnation
of the DNA was carried out as described above. After plating and incubation
OIN at 37°, very large colonies were selected and inoculated into 3ml LB
ampicillin cultures. The DNA from BJ5183 cells is not stable, and must
therefore be transfonned into XLI-Blue cells prior to screening and further
manipulation. After a 6 hour growth period, the BJ5183 cells were spun down
and subjected to standard plasmid DNA preparation techniques. A 2~1 aliquot
of the resuspended DNA was transfonned, as above, into 100~1 XLI-Blue
competent cells. DNA purified from the XLI-Blue cells was screened by
restriction analysis for desired recombination event.
BJ5183 cells were made competent as follows: A streak plate of
BJ5183 bacteria from a glycerol stock was made on solid agar without
antibiotic and placed at 37°C overnight. A single colony was selected and
inoculated into 5 ml of SOB + MgS04 in a 15ml round bottom snap-cap tube
and placed at 37°C, 225 rpm for 30 minutes. Then, 95 ml of SOB + MgS04
was inoculatcd with thc 5ml starter culturc in a 500 ml flask. Thc culture was
harvcstcd whcn thc OD(,(l{) = 0.15. Thc culture was transfcrrcd to a 5001111
disposable centrifuge bottlc and incubatcd on ice for 10 minutes. It was thcn
centrifuged at 900 - 1000 x g for 10 minutes at 4°. The supernatant was
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discarded and the bottle was left inverted for 1 minute. On ice, the pellet was
resuspended with lOml ice-cold TFB ( lOmM MES, 45mM MNCh, lOmM
CaCh, 100mM KCI, 3mM Hexamminecobalt chloride) and then an additional
23ml of ice-cold TFB was added and mixed gently by swirling. The bottle
was returned to ice for an additional 10 minutes. The cells were centrifuged at
900 - 1000 x g for 6 minutes at 4°. After the supernatant was decanted, the
pellet was re-suspended as above in 8ml ice cold TFB. DMSO was added at a
ratio of 7~1 for each 200 ~l of re-suspension. The cells were returned to ice for
an additional 10 minutes. An additional 7~1 of DMSO for each 200~1 ofre-
suspension was added. Cells were aliquoted in 200~1 volumes into pre-
chilled tubes (0.8 or 1.5ml) on dry ice and stored at _80°.
F. GENERATION, PURIFICATION, and PROPAGATION OF ADENOVIRUS
VECTORS
1. DNA Transfection for Rescue Of Recombinant Adenovirus Vectors
PER.C6™ cells in 60 mm dishes were transfected using the CaPO~
coprecipitation method (Graham and van der Eb 1973). PER.C6™ cells were
seeded in 60mm dishes so that they were 80% confluent on the day of
transfection. In a 15ml conical tube 5-1O~g Pmcl digested DNA was mixed
with 500~1 room temperature IX Hepes (21 mM HEPES. 0.137 M NaCI. 5
mM KCI. 0.7 m1'.l Na:HPO.1. 5.5 mM glucose. pH 7.1). Addition of 25~11 of
2.51'.1 CaCI was done drop-wise to the tube with gently mixing. After 30
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minutes, the cells to be transfected were rinsed with Opti-MEM (Gibco #
31985-070) and then fed with Opti-MEM containing 1% FBS and 1%
Penn/Strep/Glu. The precipitate was added drop-wise to the cells. Media was
changed the following day to Williams E with 10% PBS, 1% Penn/Strep/Glu.
Cells were monitored for CPE.
2. Preparation Of High Titer Viral Stocks
To prepare purified virus stocks, cells and media from two 2- layer
NUNC cell factories were harvested following complete CPE and the cells
were pelleted at 4,500 rpm for 10 minutes. The media was removed and the
cell pellet was resuspended in 12 ml A105 or A195 buffer and placed into a
50ml conical tube. Following three cycles of freezing in a dry ice ethanol
bath followed by thawing at 37° , the lysate was centrifuged for 10 minutes at
3000rpm to pellet the cell debris. The supernatant was treated with
Benzonase (Nycomed Pharma 1059781) at 150U/ul at room temperature for
30 minutes. The supernatant was then layered onto the top of a CsCI gradient.
The gradients were prepared by pipetting 3ml of light cesium chloride
(1.20glml) into t.he bottom of a Beckman UltraClear (344059) ultracentrifuge
tube. 3ml of Heavy CsCI ( 1.45g1ml) was then pipetted underneath the light
layer. Finally, 6ml of the benzonase treated lysate was placed gently on the
top of the gradient. The tubes were spun at 35K overnight in an S\V41Ti rotor
at 4('C. Thc following day the virus was sccn as an intcnse lowcr band of
37
packaged virus with a weaker upper band representing empty capsid. The
lower bands were collected, combined, and spun on a fresh gradient as above
for a minimum of four hours. The virus was collected and dialyzed in a
SpectraJPor CE disposable dialyzer (# 08-682-58N) in 500 times the volume
of AI05 or Al95 with one change of buffer after four hours. The virus was
collected and stored at -70.
3. Viral Vector Genome Ouantitation
Viral stock quantitation was measured by TaqMan real time PCR.
Each experimental subset contains a No Template Control (NTC) and
standard curve. Quantities of each subset were calculated by the 7700
software and exported into and further calculated in a Microsoft Excel
spreadsheet. All test article manipulations were performed using a PCR
workstation with pipettes, tips, and reagents dedicated exclusively for this
purpose. Pipets were treated with DNAZap (Ambion 9890) prior to each
experiment. In A105/A195, 1O1l1 purified viral DNA was diluted lO-fold
serially until the final estimated concentration of 107genomes/lOlll was
reached. Next, 50111 diluted test article was placed into a fresh microtube
containing 50111 0.2% SDS. The samples were incubated at 56° for 10 minutes
and then allowed to coolon the bench top for 10 minutes. Samples were then
diluted 100-fold in H20.
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Master Reaction Mix was prepared as follows:
Universal Mix 25111
Forward Primer 0.1111 (lOOIlM)
Reverse Primer 0.1111(lOOIlM)
Probe 0.1111(lOOIlM)
H2O 14.7111
The final mix was distributed to the test wells of a MicroAmp optical 96-well
reaction plate (PE Applied Biosystems # 403012) in a volume of 40111. The
lysed and diluted viral stock material was added to each well in tripl~cate in
10111 volumes. Then, 10111 of each concentration of standard curve was added
to the plates in triplicate. Next, 10111 of NTC was added to the plate in
triplicate. The plate was covered with an optical adhesive cover (PE Applied
Biosystems # 4311971) and run on the ABI Prism 7900 Sequence Detection
System under the following conditions:
50°C 2 minutes 1cycle
95°C 10 minutes 1 cycle
95°C 15 seconds 40 cycles
60°C 1 minutc
with data collcction at all stagcs. Oncc thc data was savcd it was cxportcd
into Microsoft Exccl sprcadshcct tcmplatc which calculatcs avcragcs.
For Group 0 vcctors: Forward primcr 5' GCGCAGTCATIGACGCTCTA 3',
Rcvcrsc primcr 5.ATACCACGTTAGTCGCGGCT 3', and Probc
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5' TAACCCGTITGCGTICCGCCA 3'. pAd24LllilAd50rf6 DNA was
used as the standard curve.
For Seap vectors: Forward primer 5' TAACCAGTGCAACACGACACG 3',
Reverse primer, 5' TCCCACTGACTICCCTGCTT 3', and Probe
5'CGAGGTCATCTCCGTGATGAATCGG 3'. pMRK Ad5Seap DNA was
used as the standard curve.
G. PROTEIN EXPRESSION AND DETECTION
1. SEAP Expression Assays
To determine SEAP expression levels from each of the viral
constructs, ill vitro SEAP expression assays were performed. 96-well plates
of 293 cells were seeded at 5 X 104 cells/ well in 150~.d growth media. On the
following day, virus was diluted to 3.33 X 109 vp/ml (2.5 X 108 vpl75fll)
twice, independently. Next, 75fll of dilution A was placed into columns
1,3,5,7,9,and 11. Dilution B was pipetted into columns 2, 4,6,8,10 and 12.
Using a multichannel pipetter, all of the samples in row A were mixed and
75fll was transferred to row B. Samples were mixed again and 3 fold
dilutions were continued down the plate. Finally. 75fll was discarded from
row H. Columns were harvcstcd at dcsircd timc-points in duplicatc. That is
dilution A and B from column I and 2 respectively wcrc harvcstcd at thc samc
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time-point. Samples were stored at 4° until assayed. Samples were assayed
according to Phosphalight recommendations. See Serum Seap assay method
below.
2. Serum SEAP Activity
To detect SEAP expression in the sera of mice immunized with Ad
vectors expressing SEAP, a chemiluminescent detection assay (Phospha-
Light, Tropix BP300) was used. Mice were immunized intramuscularly with
the appropriate dose and then bled at days 2, 5, and 8 post-injection. The
bloods were allowed to incubate at room temperature for 2 hours or more to
allow coagulation. The tubes were then spun at 14k rpm for 4 minutes to
separate the serum which was then transferred to fresh tubes in a 96 well
format and frozen at _20° until assayed. Using the Phosphalight kit ( Tropix
BP300), 5111 serum was diluted into 45111 dilution buffer in Thermo lab
systems microlite 1+ microtiter plates (Part# 7571). Standard Curves were
generated using human placental alkaline phosphatase (Sigma P-3895)
(10,000 ng/ml, 1,000 ng/ml, 333ng/ml, Illng/ml, 37.04ng/ml, 12.3ng/ml, and
4.1ng/ml) in dilution buffer containing naive serum (Sigma S7273). The
plates were covered with tape and endogenous Seap was heat inactivated for
30 minutes at 65°C. Plates were then cooled on ice 3-5 minutes. After
cooling. 50111 assay buffer was added to each well. After 5 minutes 50~11
reaction buffer was added (CSPD substrate diluted 20 fold in reaction buffer
diluent) to all wells. After 20 minutes. light output was measured on a Dynex
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microtiter plate luminometer. Data was collected for 5 seconds using
summation for each well. Data was imported into Excel to determine serum
Seap concentrations.
3. ELISA
Enzyme linked immunosorbent assays (ELISA's) were performed to
determine the titer of specific anti-SEAP antibodies generated in immunized
mice. To determine the titer of anti-SEAP antibodies generated in immunized
mice, 96-well Nunc Maxisorb plates (Nunc 430341) were coated with IJlg of
human placental alkaline phosphatase (Sigma P-3895) in 100JlI PBS overnight
at 4°. The next day, plates were washed 5X with wash buffer (PBS 0.05%
Tween) and then incubated for 2 hours at room temperature in blocking buffer
(PBS, 1% BSA, 0.05% Tween). Following an initial 1: 10 dilution of sera, 3-
fold dilutions were made down a non-adsorbant 96-well plate in blocking
buffer. The dilutions were transferred to the coated plates. Following a 2 hour
incubation, the plates were washed 5X with wash buffer and then 100Jll of
secondary antibody (rabbit anti mouse IgG Zymed 61-06020) diluted 1:1000
in blocking buffer) was added to each well and incubated for 1 hour. The
plates were then washed as before and 100 III OPD substrate (DAKO S2045)
in H20 + H20 2 according to package directions was added to each well and
incubated for 20 minutes. 100~d 0.5M H2S04 was added to stop the reaction
and the plates were read on a plate reader at 490nm.
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Results
Group D of the human adenoviruses has over 30 members, making it the
largest of the sUb-groups. In fact, greater than 60% of the human adenoviruses
known to date are members of subgroup D. There are no known clinical problems
related to the group D's and their ability to form tumors in newborn hamsters is nil.
Currently available data indicates that nearly all group D members have significantly
lower seroprevalence than the group C's, typically 10-30% in adults whereas the C's
are typically upwards of 60%. Ad24, a member of the subgroup D, is at the lower
end of the range. Although complete Ad24 sequence information was not available at
the time these studies were initiated, it was believed that Adl7, for which there was
published sequence, could be used to circularize Ad24 and potentially other group D
genomes into the bacterial plasmids necessary for vector construction. Adl7 itself
was not a preferred choice because its seroprevalence is closer to 30%.
Construction of Ad24 E4 modified viruses. In order to determine if the addition of
Ad50rf6 to the genome of an El-deletcd non-group C serotype would allow the
vector to propagate in PER.C6™ cclls two vcctors, Ad24~El and Ad24~ElAd50rf6
werc constructcd. The Ad24tlEl vector would crcate an El delction and act as a
ncgati 'oc control for rcscuc and propagation. Ad24tlE IAd50rf6 would servc as the
positive control for rescue and propagation. Additionally. more rcfined stratcgics
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we~e planned in which the Ad24 E4 region was modified to include Ad50rf6 in its
entirety or an Ad50rf6 EIB-55 kDa binding region. The E4 region of Ad24 was
modified in the following ways; I. The entire Ad24 E4 region was deleted and
replaced with Ad50rf6 (Ad24Lllil~Ad50rf6), 2. Ad240rf6 was swapped for
Ad50rf6 (Ad24Lllil~Orf6Ad50rf6), 3. Amino acids 225-232 of Ad240rf6 were
changed to match the residues found in Ad5 thus creating a more Ad5-like EIB-
55kDa binding region (Ad24LlliIOrf6SDM) (Figure 4). To generate these constructs,
the Ad24 genome had to be circularized into a bacterial plasmid. To do this, an El-
deleted shuttle was made with Adl7 ITR' s. Bacterial recombination with WT Ad24
DNA was used to create a hybrid plasmid containing the entire Ad24 genome (Figure
5). This plasmid can then be used to introduce modifications to any part of the Ad24
genome. The Adl7 ITR cassette plasmid consists of sequences from the right
(bp34469 to 35098) end and left (bp 4 to 414 and bp 3373 to 4580) end of the Ad 17
genome. The right and left end sequences are separated by a bacterial origin of
replication and an ampicillin resistance gene. The ITR cassette contains a deletion of
EI sequences from Adl7 (bp 415-3372) with a unique Swa I site within the deletion.
Unique PlIleI sites located at the end of the viral ITR's were also engineered into the
cassette to release the Ad24 genome from plasmid sequences upon digestion. WT
Ad24 DNA was purified and co-transformed into BJ5183 cells along with the Ad 17
lTR cassette. The Ad17 sequences in the lTR cassette provide sufficient regions of
homology with the WT Ad24 viral DNA for recombination to occur.
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Figure 4. Configuration of the E4 regions of Ad24 replication defective vectors.
Shown are the strategies employed to modify the E4 region of Ad24 to allow growth
in the PER.C6™ cell line. Deletion of the Ad24 E4 coding sequence and replacement
with Ad50rf6 (Ad24Lllili1E4Ad50rf6), substitution of Ad240rf6 with Ad50rf6
(Ad24Lllili10rf6Ad50rf6), and mutation of a known EIB55K binding site within
Ad24E40rf6 (Ad24i1EIE40rf6SDM) to match that of Ad50rf6 are detailed. WT
Ad24 (top) and WT Ad5 (bottom) E4 regions are shown for comparison.
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Figure 5. Construction of an El-deleted Ad24 plasmid vector. An Ad17 ITR
cassette containing Ad17 left end sequences from bp 4 to 414 and from bp 3373 to
4580, and right end sequences from bp 34469 to 35098, separated by a bacterial
origin of replication and an ampicillin resistance gene, was recombined in BJ5183
cells along with purified WTAd24 viral DNA. Sufficient homology between Ad17
and Ad24 sequences allowed recombination to occur resulting in a plasmid that can
be used to generate virus that is fully Ad24 in all virion structural proteins defining
sero-specificity.
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Potential clones were screened by restriction analysis and correct clones were
subsequently called pAd24Lllil. pAd24Llli1 was designed to contain Ad17 sequences
from bp 4 to 414 and from bp 3373 to 4580, Ad24 bp 4588 to 34529, and Ad1? bp
34469 to 35098 (bp numbers refer to the WT sequence for both Ad1? and Ad24).
pAd24Llli1 contains the coding sequences for all Ad24 virion structural proteins that
constitute its sero-specificity (Figure 5) but was not sequenced in its entirety so the
exact break points are not known.
In order to introduce Ad50rf6 into the E1 region of the Ad24 genome,
bacterial recombination was once again used (Figure 6). An Ad50rf6 transgene
consisting of the Ad50rf6 coding region flanked by the human cytomegalovirus
(HCMV) promoter and bovine growth hormone poly A (BGHpA) was cloned into the
E1 deletion in an Ad17 shuttle vector. This shuttle was a precursor to the ITR
cassette mentioned above. The ORF6 containing shuttle vector was digested to
obtain a fragment consisting of the transgene flanked by Ad17 sequences (bp 4 to 414
and bp 3373 to 4580). The fragment was purified and co-transformed with 5waI
linearized pAd24Llli1 into BJ5183 bacteria. Clones were screened by restriction
analysis and correct clones were named pAd24~E1Ad50rf6 (Figure 6). Although the
insertion of Ad50rf6 into the El region enabled testing for vector rescue, it was not
considered useful for future vector construction since it eliminated the E I region for
insertion of transgenes.
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Figure 6. Generation of an El deleted Ad24 plasmid containing Ad50rf6 within the
El deletion. An Adl7 based shuttle vector containing Ad50rf6 flanked by the
HCMV promoter and Bovine Growth Hormone poly A within the El deletion was
recombined in BJ5l83 bacteria with SwaI -linearized pAd24Lllil DNA.
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Additionally, constitutive expression of Ad50rf6 would be undesirable in a vaccine
vector. Placing Ad50rf6 in the E4 region of the rare serotype vector under the
control of the E4 promoter eliminates both of these problems.
Ad50rf6 was introduced into the E4 region of Ad24 either as an entire Ad24
E4 replacement or as an Ad240rf6 substitution. The Ad24 E4 promoter was left
intact in either case. Placing Ad50rf6 in the E4 region of Ad24 would more closely
mimic its native environment. This strategy might enable better temporal regulation
and retains the El region for the insertion of transgenes. There was no way to
predict what effect removal of the endogenous E4 or Orf6 region might have on the
phenotype of the virus. It is possible that the native E4 or Orf6 region might still be
required even with the addition of Ad50rf6 to the Ad24 genome. For each of these
strategies the desired pre-adenovirus plasmid was generated by bacterial
recombination. Co-transformation of BJ5183 bacteria with pAd24~Orf6BstZ17I and
the appropriately constructed Ad24 E4 shuttle plasmid resulted in the generation of
the desired Ad24 based pre-Ad plasmid. pAd24~Orf6BstZI7I, a pAd24~El
derivative. contains a deletion in the E4 region from Ad24 bp 32373 to bp 33328 with
a unique BsrZ171 site. The complete sequence of pAd240rf6BstZ17I consists of
Ad17 scqucnccs from bp 4 to 414 and from bp 3373 to 4580, Ad24 bp 4588 to 32372
and from 33329 to 34529. and Ad 17 bp 34469 to 35098 (bp numbcrs refcr to the \VT
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sequences of both Ad1? and Ad24). An Ad24 E4 shuttle (pAd24Llli1LlE4Ad50rf6)
was constructed by digesting pAd24Llli1 with PmeI and BsrGI and cloning the
restriction fragment representing the E4 region (bp 31559 to 35164) into pNEB193.
The resulting plasmid is pNEBAd24E4. This DNA was digested with Acel and
EcoNI to remove the E4 coding sequences. An oligo containing BgLII and XlwI sites
(underlined) (5' ACTCGAGATGTATAGATCT 3';
5' CTAGATCTATACATCTCGAG 3') was introduced to generate pNEBAd24LlE4.
Ad50RF6 was PCR amplified using primers containing BgLII and XlwI sites
(underlined)
(5' GCACAGATCTTTGCTTCAGGAATATG 3';
5' GAGAACTCGAGGCCTACATGGGGGTAGAG 3') and cloned into
pNEBAd24~E4 at the BglII and XIIO] sites generating pNEBAd24Llli4Ad50rf6.
Finally, pNEBAd24Llli4Ad50rf6 was digested with PVll] and PmeI, the restriction
fragments sized fractionated by gel electrophoresis, and the desired fragment
containing Ad50rf6 flanked by Ad24 sequences was gel purified.
pAd24~Orf6BstZl7Iwas linearized at the BstZ17I site and recombined with the
aforementioned shuttle fragment in BJ5183 bacteria to create
pAd24~E1~E4Ad50rf6. Potential clones were screened by restriction analysis and a
correct clone was selected as the pre-adenovirus plasmid pAd24~El~E4Ad50rf6.
To construct pAd24tlEltlOrf6Ad50rf6 (an Ad24 pre-Ad plasmid
containing an El deletion as well as a deletion of Ad240rf6 substituted by Ad50rf6).
an Ad24 E4 shuttle was constructed in which the Ad240rf6 gene was replaced by
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Ad50rf6. To do this, the EcoR1 restriction fragment representing bp 32126 to bp
33442 of the Ad24 genome (encompassing the E4 Orf6 coding region), was
subcloned into the EcoRI site in pNEB 193, generating pNEBAd240rf6. In order to
delete the E4 Orf6 gene in pNEBAd240rf6 and replace it with Ad50rf6,
pNEBAd240rf6 was digested with StyI and treated with Klenow to blunt the ends
and then digested with EagI. The desired pNEBAd240rf6 fragment was then ligated
with a PCR product representing the Ad5 Orf6 gene from Ad5 bp 33193 to bp 34125,
generating pNEBAd24~Orf6Ad50rf6. The PCR primers used to generate the Ad5
Orf6 fragment (5'CGAGACGGCCGACGCAGATCTGTITG 3';
5'GAAGTCCCGGGCTACATGGGGGTAG 3') were designed to contain EagI and
SmaI sites (underlined above) for ligation with the pNEBAd240rf6 fragment. In the
final step pNEBAd24~Orf6Ad50rf6 was digested with EcoRI, the restriction
fragments were size fractionated by agarose gel electrophoresis and the desired
fragment containing Ad50rf6 flanked by Ad24 sequences was gel purified. Co-
transformation of B15183 bacteria with the EcoRI fragment and
pAd24~Orf6BstZl7I, which had been linearized in the E4 region by digestion with
BstZ17I, resulted in the generation of pAd24~1~Orf6Ad50rf6by homologous
recombination. Potential clones were screened by restriction analysis and one clone
was selected as pre-adenovirus plasmid pAd24~El~Orf6Ad50rf6. The Orf6 swap
modification would more closely mimic wild-type than the E4 deleted version since
the other Ad24 E4 proteins should be expresscd. Both Orf4 and Orf617. howevcr.
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would be Ad5/24 hybrid proteins. There was no way to predict what effect, if any,
this would have on the phenotype of the vector.
These strategies did not address the biology of the interactions that might enable
growth to occur. In the final vector, the specific amino acids in E40rf6 known to be
involved in E1B-55 kDa complex formation were changed so that they code for the
amino acid sequence found in Ad5E40rf6. This strategy not only involved the fewest
changes to the Ad24 E4 region it also addressed some important questions about
where the key interactions between E1B-55 kDa and E40rf6 occur. In order to make
the changes in the bases believed to be involved in E1B-55 kDa binding the same as
Ad50rf6 we used the Site Directed Mutagenesis Kit from Stratagene (Cat # 200518).
Primers were used to amplify pNEB Ad240rf6 DNA while introducing the desired
mutation. The modification of the Ad240rf6 region fortuitously creates a Pst! site
which was used to screen for mutagenesis. The primers are as follows;
5'ATGTGCTGCAGTTACTGTGCTGATTTAAGCGAGATCAGG 3' and
5'CCTGATCTCGCTTAAATCAGCACAGTAACTGCAGCACAT 3'. Base
changes are bolded, Pst! site underlined. Structure was confirmed by Pst! digestion.
pNEBAd240rf6SDM was sequenced and mutagenesis confirmed. No additional
bases were found to be changed. To make recombination of the Site Directed
Mutagenesis (SDM) mutated E4 region back into the Ad24 genome plasmid more
straightforward. a BamHI restriction site was removed from pAd24 by digesting it
with Pacl and re-circularizing the 9Kb fragment. The new plasmid, pAd24 BamHI
collapsed, was then cut with BamHI to linearize. The 1311 bp EcoR! fragment of
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pNEBAd240rf6SDM was isolated on a gel and purified using the Qiaquick gel
extraction kit. Recombination of the two fragments in BJ5183 cells re~ulted in
pAd24collOrf6SDM. pAd24collOrf6SDM was cut with Pad and P17leI to liberate a
-7kb fragment. pAd24Lllil was cut with N/zeI and Spel leaving 670bp and 525 bp of
homology to the ends of pAd24collOrf6SDM. Recombination in BJ5183 cells
resulted in pAd24Lllil0rf6SDM (Figure 7). This plasmid was again sequenced to
confirm only the desired bases were changed and the amino acid alignment is shown
in Figure 8. Because it was important to measure more than the growth and
infectivity of the ne,w Ad24 vectors, it was necessary to introduce a transgene into the
El region that could be used to measure expression levels and antibody responses. It
was unpredictable as to whether or not the introduction of the transgene itself would
effect how well the virus propagated. The size of the transgene, where it is expressed,
how it is transported, and whether it is toxic to the cell, are all factors that can affect
vector phenotype. Seap was chosen as the transgene to include because expression
levels both in media and in mouse sera could be measured easily as it is a secreted
protein. It would not increase the overall size of the viruses beyond the range which
is able to be packaged, and there was an Elisa in place for measuring antibody
responses in animal models.
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Figure 7. Construction of an El-deleted Ad24 veCtor modified in a region ofE40rf6
shown to bind EIB-55 kDa. pAd24Lllil DNA was cut with NlzeI and SpeI and co-
transformed with a PmeI- Pac! fragment of pAd24collapsedOrf6SDM which contains
the mutated E40rf6.
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Figure 8. Alignment of Ad5, Ad24, and Ad24LllilE40rf6SDM E40rf6 protein
sequences. 7 base pairs between amino acids 225-232 were mutated in Ad24
resulting in the 4 amino acid changes shown. This was designed to create an Ad5
Orf6- like region within Ad24LllilE40rf6SDM which would allow binding to Ad5
EIB-55 kDa present in the PER.C6™ cell line.
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The addition of Seap to any of the viruses was accomplished via
recombination, through the generation of a plasmid, pABSAdl?HCMV SEAP
BGHpA (this is the same as the El-deleted Adl? shuttle vector mentioned above with
Seap in place of Ad50rf6) containing an HCMV promoter followed by the SEAP
transgene and Bovine Growth Hormone polyA flanked on either side by Adl?
sequences. An XbaI- EcoRV digest releases the desired fragment to be used in
conjunction with SwaI cut pre-Ad plasmids described above. That is pAd24~El,
pAd24~1~E4Ad50rf6, pAd24~l~Orf6Ad50rf6, and pAd24~EIE40rf6SDM.
Recombination results in the introduction of Seap into the El region of the respective
vectors. Potential clones were screened by restriction analysis and one clone was
selected for each as a pre-adenovirus plasmid.
Rescue of Ad24 plasmid vectors into virus. Pre-Ad plasmids were rescued into
virus in PER.C6™ cells. Releasing viral ITR's from plasmid sequences is required
for viral propagation and is acheived by digesting plasmid DNA with Pille!. The
DNA was then transfected into 6 em dishes of PER.C6™ cells using the calcium
phosphate co-precipitation technique. Interestingly, all vectors, including Ad24~El
were able to be propagated in the PER.C6™ cell line. In order to confirm that the
gcnctic structure of the handcd viruscs was corrcct. the viral DNAs wcre extracted.
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digested, and end labeled with 33p . Upon visualization by autoradiography, it was
confirmed that the viral structures were correct.
Growth Kinetics of Ad24 E4 modified vectors. In order to determine if the E4
modifications had an effect on the growth characteristics of the Ad24 vectors, one
step growth curves were performed. PER.C6™ cells in 6-well plates were infected at
3000 vplcell and wells (cells and media) were harvested at various times post-
infection. The cells and media were freezel thawed three times and clarified by
centrifugation. The amount of virus present was determined by quantitative PCR and
is graphed in Figure 9. Although vector stocks for all the constructs could be
generated, the Ad50rf6-containing vectors exhibited a distinct growth advantage. To
our knowledge, this is the first report of a non group C, El-deleted vector to be
propagated by a group C complementing cell line without modification to either the
cell line or the vector. Ad24~lE40rf6SDM appears to have the same kinetics and
overall yield as Ad24~El suggesting that the mutagenesis is not sufficient to improve
growth above a vector containing endogenous Ad24E40rf6 sequences. The same
trend in relative growth kinetics is seen for the Ad24 vectors that contain Seap in El,
although the difference between vectors with or without Ad50rf6 is not as great
(Figure 10).
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Ad24 SEAP replication Kinetics
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Figures 9 and 10. Replication Kinetics of Ad24 E4-modified viruses. Virus was
infected into PER.C6™ cells at moi 3000. Cells and media were harvested at various
time points post-infection. After three rounds of freezing and thawing, clarified
supernatant was subject to quantitative PCR using Group D primer and probe sets or
Seap primer and probe sets (figure 9 and 10, respectively) to determine viral genome
number.
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The productivity of the SEAP containing Ad24LlEI and Ad24LlliIE40rf6SDM
vectors appears to be improved relative to the transgene-Iess vect6rs. To compare
productivity of the Ad24 E4-modified vectors, the virus concentration per cell was
determined (Table I). The results support the growth curve data. That is, vectors
containing Ad50rf6 are more productive than those without Ad50rf6.
Infection efficiency of Ad24-based recombinant vectors. Because the current
dosing regime as set by the FDA is determined by particle number, it would be
advantageous to develop a vector that has a low particle:infectious particle ratio, thus
maximizing the effective dose a patient would receive. Although dosing by
infectious titer would seem a more accurate measurement of the potency of the
vaccine, it is an unacceptable means of dose determination because of high assay to
assay variability. For example, it was thought that Ad5's particle to infectious particle
ratio based upon plaque assays was about 100. Using current assays, the ratio is
thought to be less than 10. In an in-house CPE based assay, two vectors, differing
only in the presence of the E3 region appeared to have different infectivity. The EI-
E3- vector seemed to be less infectious than the EI-E3+ vector. A PCR based assay
showed that the infectivities were not different; it was the ability of the virus to cause
CPE that differed and resulted in the apparent discrepancy.
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Construct
Ad24t>El
Ad24t>E1Ad50rf6
Ad24t>Elt>E4Ad50rf6
Ad24t>EIt>Orf6Ad50rf6
Ad24t>El E40rf6SDM
MOl
(vp/cell)
200
200
200
200
200
Harvest time
(hr)
72
72
72
72
72
Virus concentration
(10E3 vp/cell)
0.6
5.3
4
1.5
0.9
Table 1
Ad24t>E1Seap 200 72 4
Ad24t>E1Seap~E4Ad50rf6 200 72 6
Ad24DEl Seap~Orf6Ad50rf6 200 72 2
Ad24t>El SeapE40rf6SDM 200 72 4
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Table 1. PER.C6™ cells were infected with virus at moi 200. 72 hours post-
infection cells and media were harvested. After three rounds of freezing and thawing,
the virus concentration was determined by quantitative PCR using either Group D or
Seap specific primer and probe sets. Values shown are an average of three
independent infections of PER.C6™ cells in T-25 flasks .
•
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It is known that high doses of adenovirus can cause adverse side effects such as
inflammation and fever (St George 2003). Therefore, it is desirable to administer the
lowest effective dose to the patient. Identifying vectors with low particle: infectious
particle ratios could maximize benefits while minimizing side effects. It was therefore
important to measure how the infectivity of the Ad24 viruses containing the different
E4 modifications compared. Using a TCID50 end-point dilution assay, the infectious
titer of the Ad24El-deleted constructs was determined (Table 2). The results
dramatically demonstrate that the presence of Ad50rf6 does improve the infectivity
of Ad24 E4-modified viruses. Ad24~El and Ad24~EIE40rf6SDMare nearly 100-
fold less infective that wild type Ad24 and almost lO-fold less infective than the E4
replacement or E40rf6 substitution vectors. It is also very important to note that in
comparison to either wild type Ad5 or El-deleted AdS, the Ad24 vectors are
significantly less infective (data not shown).
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Construct
WT Ad24
Ad24~El
Ad24~E 1Ad50rf6
Ad24~El~E4Ad50rf6
Ad24~E1~Orf6Ad50rf6
Ad24~E1E40rf6SDM
Table 2
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Particle:lnfectious particle ratio
391
36,092
183
3292
837
24,692
Table 2. Determination of particle to infectious particle number. To calculate the
infectivity of our Ad24 E4-modified stocks, a TCID50 end-point dilution assay was
performed. Cells were infected in a 96-well format and allowed to replicate for 12
days. Positive wells were revealed by QPCR. The ratio of total particles to infectious
particles is shown.
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Seap expression levels and antibody response. Seap expression from the Ad24 E4
modified viruses was measured both in vitro and in vivo to determine what effect, if
any, modifications to the E4 region might have on the vectors. 293 cells were
infected from moi 5000 down to moi 2.3 and Seap activity was measured at various
time-points over a three day period. The results show that there is nearly a ten-fold
difference in expression levels between an Ad5 based vector and Ad24 based vectors
that can be seen in as little as 24 hours post-infection (Figure 11). At about 40 hours
post-infection the Seap expression from an Ad5 vectors reaches plateau because the
cells have passed complete ePE. It takes nearly 65 hours for the Ad24 vectors to
reach Seap levels that an Ad5 vector at the same moi can achieve in 24 hours. At the
lower moi's of 555 and 185, Seap levels for Ad5MRKSeap reach 1.6 X 105 and 1 X
105 nglml, respectively (data not shown). The Ad24 EI-deleted Seap constructs
barely reach levels of I X 105 nglml at the highest moi and latest time-point. The
Ad24 constructs retain the same profile through moi 20 but Seap levels remain below
1 X lOJng/ml even at the latest time-point (data not shown).
In Balb/c mice, Seap activity was measured at days 2, 5, and 8 post-injection
with doses ranging from lOs_10 10 (Figure 12). The Ad24 constructs all perfonn at the
same level as each other, but exhibit approximately lO-fold less activity at day 5 than
does an AdS-based vector. All vectors, including AdS, drop off to the same level by
day S.
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Seap expression in 293 cells
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Figure 11. Seap expression in 293 cells. Cells were infected in duplicate at an moi
of 5000 and diluted three-fold sequentially until moi 2.2 was reached. Media was
harvested at various times post infection. AdS Seap is shown for comparison. Data
from moi 5000 is representati ve of the trend at all moi' s.
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Seap activity in Balb/c mice
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Figure 12. Serum Seap activity in Balb/c mice. Balb/c mice were immunized
intramuscularly with 108, 109, or 1010 vp and bled at days 2, 5, and 8. Serum Seap
activity was measured using Tropix Phospha-Light kit. Dosing at 1010 is shown. N=5
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Interestingly, both Ad24LllilSeap and Ad24LllilSeapOrf6SDM perfonned similarly
to the Ad50rf6-containing vectors both ill vitro and ill vivo. Given their poor
infectivity, one might expect the expression levels of a transgene from these vectors
to be quite low. Based on this assay, the infectivity of the viral vector may not be
predictive of subsequent transgene expression levels from that vector.
Generation of high level expression of the transgene is desirable because of the
subsequent immune response that it is anticipated to trigger. The fact that Seap
expression levels drop off quickly could indicate an immune response to the
transgene. To investigate this, antibody responses to Seap after im injection of
viruses at 108, 109, and 1010 were measured. Figure 13 shows the results. The
responses to an Ad5 based vector are clearly superior to any of the Ad24 vectors.
Among the Ad24 based vectors either with E4 modification or without, there were no
significant differences.
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Figure 13. Seap antibody responses in Balb/c mice. Elisa assays were performed to
determine the Seap antibody responses of Balb/c mice injected with our E4 modified
Ad24 Seap constructs. Serum assayed was from mice bled 42 days post-injection.
The individual mouse titer as well as the geometric mean titer is shown. Ad5 Seap
and Ad5Lllil are included for comparison. N=5
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Discussion
It has become necessary to establish a platform for propagating non-group C
adenoviral serotypes to use as vaccine or gene therapy vectors for circumvention of
pre-existing immunity (Mastrangeli, Harvey et a1. 1996; Mack, Song et a1. 1997;
Parks, Evelegh et a1. 1999). It has been widely accepted for some time that only group
C members are capable of propagation on Ad5 E1-containing cell lines and all human
clinical trials to date have utilized solely group C members, in part, because of their
ability to be propagated on either the 293 or PER.C6™ cell lines. There have been
reports of failed complementation forthe group B E1-deleted members,
Ad7(Abrahamsen, Kong et a1. 1997) and Ad35 (Vogels, Zuijdgeest et a1. 2003). A
non-human serotype, PAV-3, was also unable to grow on Ad5E1 containing cell lines
(Zakhartchouk, Zhou et a1. 2003). This report shows that an Ad24 virus deleted in
both E1A and E1B, with very low seroprevalence in the population, was able to be
complemented in both 293 and PER.C6™ cells, both of which are Ad5 E1-containing
cell lines. To our knowledge, this report is the first to demonstrate complementation
of a non-group C, E1-deleted vector by existing cell lines without modification to
either the vector or the cell line. The lack of complementation for Ad7 was corrected
when Ad50rf6 was provided in the cell line and for Ad35 and PAV-3 when the
alternate serotypes' E I B 55-kDa was expressed in the cell line. These findings
coupled with significant data suggesting the importance of the E1B-55 kDa-E40rf6 .
interaction suggested that it was the failure of this specific interaction that led to the
so
inability of non-group C serotypes to be complemented by Ad5 El-containing cell
lines. Using straightforward recombination techniques, several vectors were
generated that placed Ad50rf6 in the genome of an Ad24EI-deleted vector. The data
indicated that the addition of Ad50rf6 to the genome of the alternate serotype being
propagated significantly improved both replication and infectivity of the virus as
measured by our assays. Although not strictly required for the growth of an Ad24
El-deleted virus, the addition of Ad50rf6 to the genome provides certain advantages
to the virus, perhaps because the Ad5EIB-55 kDa - Ad5E40rf6 interaction can
properly occur. A region from amino acids 225-232 within the Ad50rf6 region has
been shown to bind EIB-55 kDa. Disruption of this region has effects on EIB-55
kDa localization, as well as on DNA, RNA and protein synthesis. In an effort to
facilitate the proper interaction of Ad240rf6 and Ad5 EIB-55kDa, with minimal
disruption to endogenous E4, this region within Ad24E40rf6 was mutated to match
the residues found in Ad5E40rf6. This virus performed no better than the Ad24 EI-
deleted virus and it appears that mutation of this region to become Ad5-like is
insufficient to allow complete complementation of an Ad24 El-deleted virus. There
are several other regions within Ad50rf6 that have also been shown to be important
for proper function of the protein. Perhaps one of these areas either alone or in
conjunction with the 225-232 region is critical for allowing complete
complementation. Orlando and Ornelles tested certain regions within Ad50rf6 to
dctern1ine their necessity and/or sufficiency to both bind and or re-localize EIB-55
kDa. and or support viral replication (Orlando and Ornelies 2002). Their work
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focused on the arginine faced amphipathic helix that had previously been shown to be
necessary to direct nuclear localization of EIB-55 kDa protein and for enhanced viral
replication of an E4 deleted virus. Arginine substitutions in the arnphipathic helix
were analyzed. These substitutions occur just downstream of those that were
mutagenized in our study. Interestingly they found that not only are the abilities to
augment viral replication and direct nuclear localization separable, but the specific
regions required may be different for Orf6- EIB-55 kDa binding in vitro than those
necessary for Orf6 function in a productive viral infection. Our E40rf6 225-232
Ad5 matched vector does not show growth improvement over Ad24L1EI but might
exhibit improvement in binding and or shuttling of the EIB-55 kDa - E40rf6
proteins. It would be interesting to repeat the binding and localization studies done
on Ad5 vectors with our vectors. It is also important to determine the levels of Orf6
expression within the vectors. It is reasonable to assume that there is enough
expression to allow some level of complementation, but beyond that, it is difficult to
determine what effect the modifications may have had on Orf6 expression levels
within the vectors and what effect this in turn has on the phenotype of the virus.
We and others (Vogels, Zuijdgeest et al. 2003)(Abrahamsen, Kong et al.
1997) have found that sub-group B of the human adenoviruses is unable to be
complemented by the Ad5EI region contained in existing cell lines. Addition of
Ad50rf6 to the genomes of both Ad35 and Ad34 allowed robust growth in the
PER.C6™ cell line (data not shown). Growth ofEI-deleted Ads 7.14.16. and 21. all
group B members. was also possible on a cell line expressing Ad50rf6 (data not
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shown). It would be of interest to know if the Ad35 EIB-55 kDa containing cell line
(PERC6™ /55K) could support the growth of other group B members. Given the
apparent requirement of group B EI-deleted viruses for a sero-matched EIB-55 kDa-
E40rf6 interaction, it appears that the group B's would serve as a better model for
defining the importance of the regions within E40rf6 that have been reported to have
/
physical and or functional interactions with EIB-55 kDa.
The infectious titers of the Ad24 EI-deleted viruses, regardless of the E4-
modifications they contained, were found to be significantly lower than that of an
Ad5 EI-deleted vector. Addition of Ad50rf6 to the genome of an EI-deleted Ad24
virus improved infectivity over non-Ad50rf6 viruses nearly lO-fold. Vogels et al.
reported that the Ad35 serotype has a virus particle per infectious unit ratio
approximately six-fold higher than that for Ad5 (Vogels, Zuijdgeest et al. 2003) and
this may be a characteristic of many of the alternate serotype adenoviruses. Because
the alternate serotype vectors will not be vulnerable to neutralization by anti-Ad5
antibodies in the patient, the lower infectivity might still elicit comparable immune
responses when compared to Ad5-based vectors. In any case, there are over 50
human adenoviral serotypes which can be screened for favorable infectious titers and
low seroprevalence prior to development as a vaccine or gene therapy candidate. The
authors also noted that the harvest times for their Ad35 vcctors diffcr from what is
known to be optimal for an AdS vcctor (Vogels. Zuijdgeest et al. 2003). This was also
true for Ad24 and sevcral othcr group 0 mcmbcrs indicating that optimization of AdS
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based protocols will be necessary and should make alternate serotype candidates a
more viable option than they might initially appear.
In light of the growth and infectivity data, it appears that a viable vaccine
candidate for large scale production will have to contain Ad50rf6 within its genome.
Although the deletion of non-essential E4 Qrfs permits extra space in the vectors,
while still allowing growth in PER.C6™, the effects that these alterations might have
on parameters such as transgene expression and immunogenicity were unclear. Two
of the vectors contained either full or partial deletion of the E4 region of Ad24. There
have been reports of variable transgene expression from Ad5 vectors containing E4
modifications. Significant work has been done to investigate the role of E4 and its
QRFs on the regulation of gene expression and its subsequent effect on the immune
response (Tauber and Dobner 2001). For some gene therapy applications such as for
chronic diseases, it is desirable to have the transgene of interest expressed over a long
period of time. Several studies have indicated that CMI responses to viral antigens are
a principal factor in the elimination of transduced cells and loss of transgene
expression (Yang, Nunes et al. 1994; Yang, Li et al. 1995; Zsengeller, Wert et al.
1995). In addition to El deletion, E4 modifications have been made to vectors to
rcduce or completely eliminate the potential for viral gene expression and therefore
climinate the CMI response to viral antigcns. As statcd previously, E4 has bccn
shown to be involved in viral DNA replication, as well as late gene cxprcssion. With
this in mind. Anncntano ct al. testcd whcthcr or not an El-deletcd Ad2 ,·cctor. also
delcted in E4 with thc cxception of Orf6 might havc a reduccd potcntial for viral gene
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expression as compared to a vector containing a WT E4 region and whether this
would result in a subsequent reduction of CMI responses and persistence of transgene
expression (Armentano, Zabner et al. 1997). The expression of p-gal from an
HCMV promoter in a WT E4 vector, an E4-deleted vector, and an E4-deleted Orf6-
containing vector was compared in nude mice. Persistent transgene expression was
only seen in the WT E4 context suggesting a positive regulatory role for E4 in
persistence of transgene expression. The E40rf6 modified virus performed poorly in
immunocompetent mice as well as in nude mice indicating that the Orf6 modification
does not have a beneficial effect on the persistence of gene expression. The
difference in expression between the WT E4 and the E40rf6 vector in the nude mice
indicated there are non-immunological responses involved in persistence that likely
can be attributed to the E4 modification.
Other groups (Brough, Hsu et al. 1997) have also made El-deletedlE4-deleted
vectors believing that the reduced viral protein expression and reduced viral
replication from these vectors would allow transgene persistence. Using p-gal under
the Rous Sarcoma Virus (RSV) promoter, they found that in immunocompetent mice,
neither vector genome clearance nor transgene expression was affected by the E4
deletion in lung or liver. That is, both vectors had been cleared to 1% of input by two
weeks, and expression levels remained equal to each other showing reduction by day
7. In immunocompromised (nude) mice, although genome clearance profiles lookcd
similar, confinning the T-cell role in genome clearance. gene exprcssion levels varied
betwccn the E4+ and the E4-mice. The profiles, although similar at day 2. varied
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greatly at days 14 and 35 with El-minus E4-minus dropping to baseline levels while
El- E4+ remained at day 2 levels. Despite the vector genome clearance, expression
levels remain high. Could E4 be inducing transgene expression over time? The
authors found that the transcriptional potential of the El-minus transgene expression
cassette does seem to be enhanced relative to the El-minus E4-minus expression
cassette, implying that transcriptional activation of the transgene expression cassette
is critical for this vector. In addition, this group studied Seap expression from a CMV
promoter cassette in various strains of immunodeficient mice. In all strains, the
amount of vector genome decreased over time for both the El- and EI-E4- vectors.
The level of transgene expression per genome increased in both NIH Swiss and
Balb/c nude mice. SCID-beige mice which lack not only T and B cells, but are
defective/impaired in cytotoxic T cells, macrophages, and NK cell showed a lesser,
but significant increase in expression levels per genome. This suggests that some
mechanism other than a purely immunological one is likely involved in vector
genome clearance. In the EI-E4- containing Seap cassette, transgene expression per
vector genome decreased -8 fold by day 21. So, in addition to a significant loss in
vector genomes, the CMV expression cassette in an EI-E4- vector backbone is
inactivated. These investigators showed that transgene expression levels from CMV
and RSV promoter expression cassettes are affected by the presence of E4 products.
Ela (Armentano, Zabner et a1. 1997) and Pol III promoters (Brough, Hsu et a1. 1997)
were not affected in the same way. These studies show that the E4 region proteins
pro\"ide an enhanced cellular en\"ironment for transgene expression.
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To examine the role of the host CTL response to adenovirus as relates to the
transience of transgene expression from adenoviral vectors ill vivo, cells were infected
with El deleted Ad vectors containing intact E3 and E4 regions and were shown to be
resistant to lysis by Ad specific CTL's (Kaplan, Annentano et al. 1999). This was
seen in Ad2 and Ad5 vectors using different transgenes and different promoters.
Both Balb/c and C57BU6 strains were used. It appears that regions within E4 are
necessary for the resistance to CTL destruction, as deletion of the E4 region led to
increased susceptibility to lysis by Ad CTL's. To identify E4 elements involved in
protection from CTL lysis, vectors expressing individual E4 Orfs were constructed.
Using vectors containing an intact E3 region but only Orf6, Orf4, or Orf 6/7 from the
E4 region it was demonstrated that while Orf6 alone provided no protection, Orf 6/7
was able to provide partial protection and Orf4 provided complete protection from
CTL lysis. It is unclear how any of the known activities of these regions might be
capable of this affect. The deletion of Ad24 E4 in Ad24~EILlli4Ad50rf6 and/or the
generation of hybrid E4 Orf4 and Orf6/7 proteins within the Ad24~El~Orf6Ad50rf6
vectors might have unpredictable effects on transgene pcrsistence and or
immunological rcsponses.
Our vcctors showcd equal abilities to express Seap in 293 cells, reaching
Icvels similar to that of an AS-based vector. When administered to Balb/c mice, the
Ad24 E4 modified vectors perfomled no differently than those with an intact E4
region in our studies. The transgene expression declined to the same point as an AdS
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vector by day 8. Antibody responses to Seap, driven by the HCMV promoter in our
vectors are similar, regardless of the E4 modification. In other studies, we found that
group B vectors containing an intact E4 region were no more immunogenic that
group B vectors that were deleted in E4 but contained Ad50rf6 (data not shown).
There may be promoter effects, mouse strain differences, cell line and tissue type
differences as well as vector modification effects that will influence experimental
outcome as seen with Ad5 vectors. It could also be that the group D adenoviruses are
not as sensitive to variations in these criteria as the group C viruses seem to be.
Our approach utilizes basic recombinatorial biology to introduce El deletions
and E4 modifications to any WT group D virus rendering it replication-incompetent
yet viable for growth in existing cell lines. Screening serotypes for low
seroprevalence and high infectivity will narrow the selection of group D's to be
carried forward as potential vaccine candidates. This strategy should allow
development of a panel of vaccine delivery vehicles that will not be subject to
neutralization via pre-existing immunity and can be used to deliver multiple different
vaccines or repeated administration of the same vaccine.
ss
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